ESR1 and neoplasm: A partial response was observed in the hormone-resistant cohort treated with epigenetic therapy alone, due to the fact that DNA methylation is more abundant in estrogen-receptor-positive tumours than in basal-like tumours, which are usually triple-negative breast cancers [110].